Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.

from News-Medical.Net Mesothelioma News Feed http://www.news-medical.net/news/20160119/Bevacizumab-extends-survival-of-pleural-mesothelioma-patients.aspx